Home Daily Intelligence Tracker
    • Plans Blog Contact
    Ascendis Pharma AS logo
    ASND

    Ascendis Pharma AS

    MaveScore 24 Low model confidence
    Last Price US$270.45 As of Jul 10, 2026
    Market Cap US$17.0b Company size context
    7D Performance -1.48% Past 7 days
    1Y Performance 53.25% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Updating

    Refreshing

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    10/16

    6 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 24 Low confidence

    Stored data quality

    Freshness and coverage checks

    10/16 Partial or delayed snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Needs Data

    Financial strength needs live profitability and cash-flow fields.

    Valuation Support

    0/15 Needs Data

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    Momentum

    10/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Ascendis Pharma AS Overview

    Industry: Biotechnology

    Sector: Healthcare

    Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; Tran Read More

    Ascendis Pharma AS is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Ascendis Pharma AS

    Score

    Reported Results

    No latest earnings report cached yet

    Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

    Recent News



    Earnings Per Share

    Score 3.00/5
    Ascendis Pharma AS boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.95/5
    Ascendis Pharma AS exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Ascendis Pha... ASND US$17.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Ascendis Pharma AS olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Ascendis Pha... ASND US$17.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.42/5
    Ascendis Pharma AS attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Ascendis Pha... ASND US$17.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Ascendis Pharma AS logo

    Ascendis Pharma AS

    US$270.45

    US$17.0b

    -1.48%

    53.25%